UB Paderborn / Katalog / Suche / in CDI

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

The lancet. Diabetes & endocrinology, 2015-12, Vol.3 (12), p.948-957

2015

Volltextzugriff (PDF)

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures

Journal of bone and mineral research, 2010-02, Vol.25 (2), p.404-414

2010

Volltextzugriff (PDF)

Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

Journal of bone and mineral research, 2018-02, Vol.33 (2), p.298-306

2018

Volltextzugriff (PDF)

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

Journal of bone and mineral research, 2015-09, Vol.30 (9), p.1717-1725

2015

Volltextzugriff (PDF)

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Journal of bone and mineral research, 2013-04, Vol.28 (4), p.746-752

2013

Volltextzugriff (PDF)

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study

The journal of clinical endocrinology and metabolism, 2016-04, Vol.101 (4), p.1353-1363

2016

Volltextzugriff (PDF)

CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab

Frontiers in immunology, 2021-11, Vol.12, p.794638-794638

2021

Volltextzugriff (PDF)

Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test

Therapeutic advances in musculoskeletal disease, 2019-01, Vol.11, p.1759720X19856012-1759720X19856012

2019

Volltextzugriff (PDF)

Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial

The journal of clinical endocrinology and metabolism, 2012-08, Vol.97 (8), p.2799-2808

2012

Volltextzugriff (PDF)

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial

Journal of bone and mineral research, 2016-07, Vol.31 (7), p.1429-1439

2016

Volltextzugriff (PDF)

Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology

Bone (New York, N.Y.), 2015-12, Vol.81, p.122-130

2015

Volltextzugriff (PDF)

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial

The Journal of the American Dental Association (1939), 2008-01, Vol.139 (1), p.32

2008

Volltextzugriff (PDF)

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass

Bone (New York, N.Y.), 2007-04, Vol.40 (4), p.843-851

2007

Volltextzugriff (PDF)

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Clinical therapeutics, 2009-04, Vol.31 (4), p.751-761

2009

Volltextzugriff (PDF)

Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial

Journal of hepatology, 2022-07, Vol.77, p.S713

2022

Volltextzugriff (PDF)

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Journal of bone and mineral research, 2021-11, Vol.36 (11), p.2139-2152

2021

Volltextzugriff (PDF)

Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-17-08

2022

Volltextzugriff (PDF)

Reply to Viel

Clinical infectious diseases, 2022-10, Vol.75 (8), p.1486-1487

2022

Volltextzugriff (PDF)

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Clinical infectious diseases, 2022-09, Vol.75 (7), p.1232-1234

2022

Volltextzugriff (PDF)

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

The Lancet (British edition), 2009-04, Vol.373 (9671), p.1253-1263

2009

Volltextzugriff (PDF)

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

The journal of clinical endocrinology and metabolism, 2009-10, Vol.94 (10), p.3772-3780

2009

Volltextzugriff (PDF)

Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study

Diabetes care, 2014-12, Vol.37 (12), p.3253-3261

2014

Volltextzugriff (PDF)

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture

Menopause (New York, N.Y.), 2013-02, Vol.20 (2), p.130

2013

Volltextzugriff (PDF)

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

Bone (New York, N.Y.), 2010, Vol.46, p.S33-S33

2010

Volltextzugriff (PDF)

Efficacy of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women With Postmenopausal Osteoporosis

Journal of clinical densitometry, 2012-10, Vol.15 (4), p.495-496

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures

Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study

CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab

Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test

Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial

Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)

Reply to Viel

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

Efficacy of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women With Postmenopausal Osteoporosis

Suchergebnisse filtern